Loading stock data…
NCEL
$3.87+0.02 (+0.40%)
Market OpenUpdated 10:40 AM EDT
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
NewcelX Ltd. in the Healthcare sector is trading at $3.87. The stock is currently near its 52-week low of $1.83, remaining 58.3% below its 200-day moving average. Technical signals show neutral RSI of 62 and bullish MACD crossover, explaining why NCEL maintains its current current market pressure. The Whystock Score of 15/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 62) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.87
Potential Upside
5%
Whystock Fair Value$4.06
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
NewcelX Ltd., a biotechnology company, engages in developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company was founded in 2008 and is headquartered in Zurich, Switzerland.
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$18.48M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.57
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
122.51%
Volume
Today's trading volume
13,710
Recent News
Despite NewcelX's Pullback, Insiders Still Gained ₪136k
Insiders who bought NewcelX Ltd. ( NASDAQ:NCEL ) in the last 12 months may probably not pay attention to the stock's...
Owning 58% in NewcelX Ltd. (NASDAQ:NCEL) means that insiders are heavily invested in the company's future
Key Insights NewcelX's significant insider ownership suggests inherent interests in company's expansion 58% of the...